Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Gross Margin (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Gross Margin for 15 consecutive years, with 64.14% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin rose 166.0% to 64.14% in Q4 2025 year-over-year; TTM through Dec 2025 was 64.28%, a 244.0% increase, with the full-year FY2025 number at 64.28%, up 244.0% from a year prior.
  • Gross Margin was 64.14% for Q4 2025 at Niagen Bioscience, down from 64.52% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 65.0% in Q2 2025 to a low of 57.23% in Q4 2022.
  • A 5-year average of 61.58% and a median of 61.1% in 2021 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: soared 495bps in 2021, then plummeted -397bps in 2022.
  • Niagen Bioscience's Gross Margin stood at 61.2% in 2021, then decreased by -6bps to 57.23% in 2022, then grew by 7bps to 61.04% in 2023, then rose by 2bps to 62.48% in 2024, then grew by 3bps to 64.14% in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Gross Margin are 64.14% (Q4 2025), 64.52% (Q3 2025), and 65.0% (Q2 2025).